Compare SVC & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SVC | CSTL |
|---|---|---|
| Founded | 1995 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 839.2M | 722.8M |
| IPO Year | 1995 | 2019 |
| Metric | SVC | CSTL |
|---|---|---|
| Price | $6.60 | $35.55 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $2.50 | ★ $45.50 |
| AVG Volume (30 Days) | ★ 1.4M | 275.1K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.67% | N/A |
| EPS Growth | ★ 26.95 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,814,838,000.00 | $344,229,000.00 |
| Revenue This Year | N/A | $2.42 |
| Revenue Next Year | $1.39 | $12.69 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 3.66 |
| 52 Week Low | $1.13 | $17.72 |
| 52 Week High | $9.02 | $44.28 |
| Indicator | SVC | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 35.51 | 62.92 |
| Support Level | $6.41 | $22.88 |
| Resistance Level | $8.26 | $36.85 |
| Average True Range (ATR) | 0.23 | 1.41 |
| MACD | -0.04 | -0.07 |
| Stochastic Oscillator | 14.11 | 75.97 |
Service Properties Trust is a real estate investment trust that owns hotel properties. These properties are located in the United States, along with Canada and Puerto Rico. The company operates through its segments hotel investment unit, and net lease investments. The firm derives the majority of its revenue from the hotel real estate investments unit. The hotels are distinguished between their service levels, which include full service, select service, and extended stay; and chain scale, which includes luxury, upper upscale, upscale, upper midscale, and midscale. The hotels are extended stay or upscale. Some of the hotel brands include Courtyard by Marriott, Royal Sonesta, Crowne Plaza, Hyatt Place, and others.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.